Teza Capital Management LLC Lowers Holdings in Option Care Health, Inc. $OPCH

Key Points

• Teza Capital Management LLC has reduced its holdings in Option Care Health by 62.9%, owning 16,514 shares worth approximately $577,000.
• Analysts have given Option Care Health a consensus rating of "Moderate Buy" with a price target of $35.75, as multiple firms have recently raised their price targets, reflecting positive sentiment.
• Insider transactions showed significant purchases by directors, with Timothy P. Sullivan buying 20,000 shares and Harry M. Jansen Kraemer, Jr. acquiring 36,000 shares, indicating strong confidence in the company’s future.

Teza Capital Management LLC decreased its stake in shares of Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 62.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,514 shares of the company's stock after selling 27,982 shares during the quarter. Teza Capital Management LLC's holdings in Option Care Health were worth $577,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in OPCH. Northwestern Mutual Wealth Management Co. increased its position in Option Care Health by 1,492.9% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 892 shares of the company's stock valued at $31,000 after purchasing an additional 836 shares during the period. Brooklyn Investment Group increased its position in Option Care Health by 186.6% during the 1st quarter. Brooklyn Investment Group now owns 1,198 shares of the company's stock valued at $42,000 after purchasing an additional 780 shares during the period. Public Employees Retirement System of Ohio increased its position in Option Care Health by 21.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock valued at $43,000 after purchasing an additional 332 shares during the period. Bessemer Group Inc. increased its position in Option Care Health by 62.3% during the 1st quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock valued at $54,000 after purchasing an additional 599 shares during the period. Finally, Wealthquest Corp purchased a new position in Option Care Health during the 1st quarter valued at about $66,000. Institutional investors own 98.05% of the company's stock.

Option Care Health Price Performance

Shares of NASDAQ OPCH traded down $0.89 during mid-day trading on Friday, reaching $28.48. The company's stock had a trading volume of 1,626,043 shares, compared to its average volume of 1,842,623. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $35.53. The stock has a market capitalization of $4.62 billion, a P/E ratio of 22.78, a P/E/G ratio of 1.79 and a beta of 0.82. The stock has a 50-day moving average of $29.09 and a two-hundred day moving average of $31.43. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.00 and a current ratio of 1.52.

Option Care Health (NASDAQ:OPCH - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.01. Option Care Health had a net margin of 3.93% and a return on equity of 17.53%. The firm had revenue of $1.42 billion during the quarter, compared to analysts' expectations of $1.35 billion. During the same period last year, the business earned $0.30 earnings per share. Option Care Health's revenue was up 15.4% compared to the same quarter last year. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. On average, equities research analysts anticipate that Option Care Health, Inc. will post 1.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on OPCH. Citigroup reissued an "outperform" rating on shares of Option Care Health in a research report on Thursday, July 31st. JMP Securities raised their target price on Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a research note on Thursday, July 31st. Finally, Barrington Research reaffirmed an "outperform" rating and set a $38.00 target price on shares of Option Care Health in a report on Thursday, July 10th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Option Care Health currently has an average rating of "Moderate Buy" and a consensus price target of $35.75.

Insider Buying and Selling

In related news, Director Norman L. Wright bought 3,411 shares of the stock in a transaction on Tuesday, September 9th. The stock was bought at an average price of $29.31 per share, with a total value of $99,976.41. Following the completion of the purchase, the director directly owned 15,501 shares in the company, valued at $454,334.31. This represents a 28.21% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Harry M. Jansen Kraemer, Jr. bought 36,000 shares of the stock in a transaction on Wednesday, August 20th. The shares were bought at an average cost of $27.15 per share, with a total value of $977,400.00. Following the purchase, the director owned 375,390 shares of the company's stock, valued at $10,191,838.50. This trade represents a 10.61% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 59,411 shares of company stock worth $1,627,576. Insiders own 0.64% of the company's stock.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.